Cochrane · systematic review · CD007545
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative people at risk of active TB
Sharma, SK, Sharma, A, Kadhiravan, T, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 31.3%Low 2 · 12.5%Moderate 6 · 37.5%High 3 · 18.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rifampicin compared to isoniazid for preventing active TB in HIV‐negative people
Population: HIV‐negative people at risk of TB infection1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB Rifampicin vs isoniazid | RR 0.81 [0.47, 1.4] | 1 study · 332 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adherence6 Rifampicin vs isoniazid | RR 1.19 [1.01, 1.3] | 5 studies · 1768 participants | Moderate Downgraded: risk of bias |
Treatment‐limiting adverse events Rifampicin vs isoniazid | RR 0.48 [0.23, 1] | 4 studies · 1674 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Hepatotoxicity:13 Grade 3 and 4 toxicity Rifampicin vs isoniazid | RR 0.15 [0.07, 0.4] | 5 studies · 1774 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Rifampicin plus isoniazid compared to isoniazid for preventing active TB in HIV‐negative people
Population: HIV‐negative people at risk of TB infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB Rifampicin plus isoniazid vs isoniazid | RR 1.08 [0.65, 1.79] | 1 study · 328 participants | Very low Downgraded: inconsistency |
Adherence Rifampicin plus isoniazid vs isoniazid | RR 1.07 [0.98, 1.17] | 2 studies · 524 participants | High |
Treatment‐limiting adverse events Rifampicin plus isoniazid vs isoniazid | RR 1.16 [0.74, 1.82] | 2 studies · 536 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Hepatotoxicity Rifampicin plus isoniazid vs isoniazid | RR 0.88 [0.43, 1.81] | 2 studies · 536 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Rifampicin plus pyrazinamide compared to isoniazid in preventing active TB in HIV‐negative people
Population: HIV‐negative people at risk of TB infection1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB: Rifampicin plus pyrazinamide vs isoniazid | RR 1.32 [0.42, 4.13] | 2 studies · 176 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adherence Rifampicin plus pyrazinamide vs isoniazid | RR 1.06 [0.86, 1.29] | 4 studies · 700 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment‐limiting adverse events Rifampicin plus pyrazinamide vs isoniazid | RR 3.61 [1.82, 7.19] | 2 studies · 368 participants | High |
Hepatotoxicity Rifampicin plus pyrazinamide vs isoniazid | RR 4.59 [2.14, 9.85] | 3 studies · 540 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Rifapentine plus isoniazid weekly compared to isoniazid daily for preventing active TB in HIV‐negative people at risk of TB infection
Population: HIV‐negative people at risk of TB infection1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB Rifapentine plus isoniazid weekly vs isoniazid daily | RR 0.44 [0.18, 1.07] | 1 study · 7731 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Adherence Rifapentine plus isoniazid weekly vs isoniazid daily | RR 1.19 [1.16, 1.22] | 1 study · 7731 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Treatment‐limiting adverse events Rifapentine plus isoniazid weekly vs isoniazid daily | RR 1.32 [1.07, 1.64] | 1 study · 7731 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Hepatotoxicity Rifapentine plus isoniazid weekly vs isoniazid daily | RR 0.16 [0.1, 0.27] | 1 study · 7799 participants | High |